<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03496207</url>
  </required_header>
  <id_info>
    <org_study_id>A011-09</org_study_id>
    <secondary_id>2017-004738-27</secondary_id>
    <nct_id>NCT03496207</nct_id>
  </id_info>
  <brief_title>A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)</brief_title>
  <acronym>PULSAR</acronym>
  <official_title>A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acceleron Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acceleron Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study A011-09 is designed to assesses the efficacy and safety of sotatercept (ACE-011)
      relative to placebo in adults with pulmonary arterial hypertension (PAH). Eligible
      participants will receive study treatment for 6 months in the Placebo-Controlled Treatment
      Period, and then will be eligible to enroll into an 18- month Extension Period during which
      all participants will receive sotatercept. All treated patients will be also undergo
      follow-up period after last study drug treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, double blind, randomized, placebo-controlled, parallel-group study of
      sotatercept plus SOC versus placebo plus SOC in participants with PAH of WHO Group 1,
      functional class II-III.

      Participants will be randomly assigned in a 3:3:4 ratio to receive placebo every 21 days,
      sotatercept 0.3 mg/kg subcutaneously (SC) every 21 days, or sotatercept 0.7 mg/kg SC every 21
      days, for a period of 24 weeks in the Placebo-Controlled Treatment Period of the study while
      on standard of care therapy. Evaluations will include changes in pulmonary vascular
      resistance (PVR), six-minute-walk distance (6MWD), quality of life questionnaires,
      echocardiographic parameters, and safety. Participants who have not discontinued early from
      the Placebo-Controlled Treatment Period and have had their post-Treatment Period PVR
      assessment will be able to continue into the 18-month Extension Period in which
      sotatercept-treated participants will receive their latest dose level of sotatercept SC every
      21 days and placebo-treated participants willbe re-randomized 1:1 to receive sotatercept 0.3
      mg/kg SC every 21 days or sotatercept 0.7 mg/kg SC every 21 days while on standard of care
      therapy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 27, 2018</start_date>
  <completion_date type="Anticipated">May 16, 2022</completion_date>
  <primary_completion_date type="Actual">January 27, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Pulmonary Vascular Resistance (PVR) as measured by right heart catheterization</measure>
    <time_frame>From initiation of treatment (Study Day 1) to end of placebo-controlled treatment period (Study Day 168)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 6-Minute Walk Distance (6MWD)</measure>
    <time_frame>From initiation of treatment (Study Day 1) to end of placebo-controlled treatment period (Study Day 168)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in amino-terminal brain natriuretic propeptide (NT-proBNP)</measure>
    <time_frame>From initiation of treatment (Study Day 1) to end of placebo-controlled treatment period (Study Day 168)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in tricuspid annular plane systolic excursion (TAPSE) by echocardiography (ECHO)</measure>
    <time_frame>From initiation of treatment (Study Day 1) to end of placebo-controlled treatment period (Study Day 168)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) patient-reported outcome (PRO) score</measure>
    <time_frame>From initiation of treatment (Study Day 1) to end of placebo-controlled treatment period (Study Day 168)</time_frame>
    <description>The CAMPHOR questionnaire contains 65 items in total, 25 relating to symptoms, 15 relating to activities, and 25 relating to Quality of Life (QoL). It is negatively weighted; a higher score indicates worse QoL and greater functional limitation. Symptom and QoL items are both scored out of 25: &quot;yes/true&quot; scores 1 and &quot;no/not true&quot; scores 0. Activity items have three possible responses (score 0-2), giving a score out of 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 36-Item Short Form Health Survey (SF-36) patient-reported outcome (PRO) score</measure>
    <time_frame>From initiation of treatment (Study Day 1) to end of placebo-controlled treatment period (Study Day 168)</time_frame>
    <description>The SF-36 questionnaire is a 36-item, patient-reported survey of patient health. The questionnaire consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo SC every 21 days plus SOC for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sotatercept 0.3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sotatercept, 0.3 mg/kg SC every 21 days plus SOC for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sotatercept 0.7 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sotatercept, 0.7 mg/kg SC every 21 days plus SOC for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sotatercept</intervention_name>
    <description>Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1</description>
    <arm_group_label>Sotatercept 0.3 mg/kg</arm_group_label>
    <arm_group_label>Sotatercept 0.7 mg/kg</arm_group_label>
    <other_name>ACE-011</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. Documented diagnostic right heart catheterization (RHC) at any time prior to Screening
             confirming diagnosis of WHO diagnostic pulmonary hypertension Group I: PAH in any of
             the following subtypes:

               -  Idiopathic

               -  Heritable PAH

               -  Drug- or toxin-induced PAH

               -  PAH associated with connective tissue disease

               -  PAH associated with simple, congenital systemic-to-pulmonary shunts at least 1
                  year following shunt repair

          3. Symptomatic pulmonary hypertension classified as WHO functional class II or III

          4. Screening RHC documenting a minimum PVR of ≥ 400 dyn·sec/cm5 (5 Wood units)

          5. Pulmonary function tests (PFTs) within 6 months prior to Screening as follows:

               1. Total lung capacity (TLC) &gt; 70% predicted; or if between 60 to70% predicted, or
                  not possible to be determined, confirmatory high-resolution computed tomography
                  (CT) indicating no more than mild interstitial lung disease (ILD), per
                  investigator interpretation, or

               2. Forced expiratory volume (first second) (FEV1)/ forced vital capacity (FVC) &gt; 70%
                  predicted

          6. Ventilation-perfusion (VQ) scan (or, if unavailable a negative CT pulmonary angiogram
             [CTPA] result, or pulmonary angiography result), any time prior to Screening Visit or
             conducted during the Screening Period, with normal or low probability result),

          7. No contraindication per investigator for RHC during the study

          8. 6MWD ≥ 150 and ≤ 550 meters repeated twice at Screening and both values within 15% of
             each other, calculated from the highest value

          9. PAH therapy at stable (per investigator) dose levels of SOC therapies

        Exclusion Criteria:

          1. Stopped receiving any pulmonary hypertension chronic general supportive therapy (e.g,
             diuretics, oxygen, anticoagulants, digoxin) within 60 days prior to study visit C1D1

          2. Received intravenous inotropes (e.g., dobutamine, dopamine, norepinephrine,
             vasopressin) within 30 days prior to study visit C1D1

          3. History of atrial septostomy within 180 days prior to Screening

          4. History of more than mild obstructive sleep apnea that is untreated

          5. Known history of portal hypertension or chronic liver disease, including hepatitis B
             and/or hepatitis C (with evidence of recent infection and/or active virus
             replication), defined as mild to severe hepatic impairment (Child-Pugh Class A-C)

          6. History of human immunodeficiency virus infection-associated PAH

          7. Prior exposure to sotatercept (ACE-011) or luspatercept (ACE-536)

          8. Uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure
             (BP) &gt; 160 mm Hg or sitting diastolic blood pressure &gt; 100 mm Hg during Screening
             Visit after a period of rest

          9. Systolic BP &lt; 90 mmHg during Screening or at baseline

         10. History of known pericardial constriction

         11. Personal or family history of long QTc syndrome or sudden cardiac death

         12. History of restrictive or congestive cardiomyopathy

         13. Left ventricular ejection fraction (LVEF) &lt; 45% on historical echocardiogram (ECHO)
             within 6 months prior to Screening Period (or done as a part of the Screening Period)
             or pulmonary capillary wedge pressure (PCWP) &gt; 15 mmHg as determined in the Screening
             Period RHC.

         14. Any current or prior history of symptomatic coronary disease (prior myocardial
             infarction, percutaneous coronary intervention, coronary artery bypass graft surgery,
             or cardiac anginal chest pain)

         15. Acutely decompensated heart failure within 30 days prior to study visit C1D1, as per
             investigator assessment

         16. Significant (≥ 2+ regurgitation) mitral regurgitation (MR) or aortic regurgitation
             (AR) valvular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pulmonary Associates, PA</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Pulmonary Specialists</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner-University Medical Center Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Health Shands Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Outpatient Health</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lindner Clinical Trial Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>New Lambton</city>
        <state>New South Whales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Madre Teresa</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30430</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade Da Santa Casa de Misericordia de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Riogrande Do Sul</state>
        <zip>90035</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dia do Pulmão</name>
      <address>
        <city>Blumenau</city>
        <state>Santa Catarina</state>
        <zip>89010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital São Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04037</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <state>Hérault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Saint Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Regensburg</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern,</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Halle (Saale)</name>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-von-Guericke-Universität Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRK Kliniken Berlin Westend</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lady Davis Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center - PPDS</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZIV Medical Center</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro-Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Complejo Hospitalario Universitario de Pontevedra</name>
      <address>
        <city>Santander</city>
        <state>Pontevedra</state>
        <zip>36071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron - PPDS</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Montecel</name>
      <address>
        <city>Pontevedra</city>
        <zip>36071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW32QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 29, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2018</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

